Literature DB >> 1868674

Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine.

W R Crom1, M V Relling, M L Christensen, G K Rivera, W E Evans.   

Abstract

The disposition of intravenous antipyrine and lorazepam, administered as model substrates for hepatic oxidative metabolism and conjugation, was evaluated in 50 children (mean age, 7.8 years; range, 2.3 to 17.8 years) with acute lymphocytic leukemia in complete remission and compared with a group of ten healthy adults. Antipyrine clearance normalized to body weight was significantly greater in children than in adults (0.91 versus 0.59 ml/min/kg; p = 0.012), but was not different when normalized to body surface area. In contrast, lorazepam total clearance (CL) and unbound clearance (CLu) normalized to body weight were not significantly different between children and adults but were smaller in children when normalized to body surface area (CL = 31.9 versus 40.6 ml/min/m2, p = 0.036; CLu = 352 versus 485 ml/min/m2, p = 0.010). The mean lorazepam fraction unbound in children was 0.087, which was not different from adult volunteers (0.084). This study has identified significant differences between children and adults in the disposition of these two compounds, with higher milliliter per minute per kilogram clearance for antipyrine but not lorazepam.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1868674     DOI: 10.1038/clpt.1991.117

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  17 in total

Review 1.  Glucuronidation in humans. Pharmacogenetic and developmental aspects.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

Review 2.  Neonatal exposure to drugs in breast milk.

Authors:  Patrick J McNamara; Maggie Abbassi
Journal:  Pharm Res       Date:  2004-04       Impact factor: 4.200

3.  Treatment use in a prospective naturalistic cohort of children and adolescents with catatonia.

Authors:  Marie Raffin; Laetitia Zugaj-Bensaou; Nicolas Bodeau; Vanessa Milhiet; Claudine Laurent; David Cohen; Angèle Consoli
Journal:  Eur Child Adolesc Psychiatry       Date:  2014-08-27       Impact factor: 4.785

4.  Developmental Regulation of Drug-Processing Genes in Livers of Germ-Free Mice.

Authors:  Felcy Pavithra Selwyn; Sunny Lihua Cheng; Theo K Bammler; Bhagwat Prasad; Marc Vrana; Curtis Klaassen; Julia Yue Cui
Journal:  Toxicol Sci       Date:  2015-06-01       Impact factor: 4.849

5.  A mechanistic approach for the scaling of clearance in children.

Authors:  Andrea N Edginton; Walter Schmitt; Barbara Voith; Stefan Willmann
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 6.  Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.

Authors:  Imke H Bartelink; Carin M A Rademaker; Alfred F A M Schobben; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

7.  Pharmacokinetics of intravenous lorazepam in pediatric patients with and without status epilepticus.

Authors:  James M Chamberlain; Edmund V Capparelli; Kathleen M Brown; Cheryl W Vance; Kathleen Lillis; Prashant Mahajan; Richard Lichenstein; Rachel M Stanley; Colleen O Davis; Stephen Gordon; Jill M Baren; John N van den Anker
Journal:  J Pediatr       Date:  2011-11-01       Impact factor: 4.406

8.  Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria.

Authors:  J S Sidhu; M Ashton; N V Huong; T N Hai; M O Karlsson; N D Sy; E N Jonsson; L D Cong
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

Review 9.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

10.  A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam.

Authors:  A R Maharaj; J S Barrett; A N Edginton
Journal:  AAPS J       Date:  2013-01-24       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.